These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
224 related items for PubMed ID: 9211757
1. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M. Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757 [Abstract] [Full Text] [Related]
2. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R. Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759 [Abstract] [Full Text] [Related]
3. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ. Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695 [Abstract] [Full Text] [Related]
5. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues. Lauriero F, Pierangeli E, Rubini G, Resta M, D'Addabbo A. Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802 [Abstract] [Full Text] [Related]
8. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N. J Endocrinol Invest; 1997 Dec; 20(7):424-8. PubMed ID: 9309542 [Abstract] [Full Text] [Related]
9. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. Verhoeff NP, Bemelman FJ, Wiersinga WM, van Royen EA. Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737 [Abstract] [Full Text] [Related]
12. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308 [Abstract] [Full Text] [Related]
13. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A. Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399 [Abstract] [Full Text] [Related]